Mind Medicine (MindMed) IncNASDAQ:MNMD
- LAST PRICE7.9500
- TODAY'S CHANGE (%)0.3400 (4.4678%)
- Bid / Lots7.9500/ 1
- Ask / Lots7.9700/ 3
- Open / Previous Close7.9800 / 7.6100
- Day Range
- 52 Week Range
- Volume560,794
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MNMD |
|---|---|---|
| 09:32 ET | 41231 | 7.79 |
| 09:33 ET | 7784 | 7.97 |
| 09:35 ET | 4611 | 7.83 |
| 09:37 ET | 11901 | 7.9093 |
| 09:39 ET | 39439 | 8.09 |
| 09:42 ET | 34863 | 8.13 |
| 09:44 ET | 12338 | 8.1 |
| 09:46 ET | 11203 | 8.055 |
| 09:48 ET | 13290 | 8 |
| 09:50 ET | 14109 | 8.03 |
| 09:51 ET | 16529 | 7.955 |
| 09:53 ET | 3597 | 7.9201 |
| 09:55 ET | 8196 | 7.87 |
| 09:57 ET | 4684 | 7.9885 |
| 10:00 ET | 2169 | 7.9243 |
| 10:02 ET | 5050 | 7.9 |
| 10:04 ET | 20282 | 7.975 |
| 10:06 ET | 1142 | 7.9692 |
| 10:08 ET | 1900 | 8 |
| 10:09 ET | 8514 | 8.025 |
| 10:11 ET | 4339 | 7.97 |
| 10:13 ET | 2945 | 7.9799 |
| 10:15 ET | 3299 | 8.01 |
| 10:18 ET | 16882 | 7.9 |
| 10:20 ET | 7969 | 7.8555 |
| 10:22 ET | 5646 | 7.86 |
| 10:24 ET | 5229 | 7.851985 |
| 10:26 ET | 12241 | 7.76 |
| 10:27 ET | 3280 | 7.8059 |
| 10:29 ET | 6550 | 7.8 |
| 10:31 ET | 2150 | 7.845 |
| 10:33 ET | 5085 | 7.8686 |
| 10:36 ET | 7533 | 7.95 |
| 10:38 ET | 4986 | 7.9999 |
| 10:40 ET | 9980 | 7.98 |
| 10:42 ET | 1741 | 7.98 |
| 10:44 ET | 18338 | 8.1 |
| 10:45 ET | 9853 | 8.025 |
| 10:47 ET | 4432 | 8.02 |
| 10:49 ET | 7291 | 8.05 |
| 10:51 ET | 6465 | 8.04 |
| 10:54 ET | 3576 | 8.0353 |
| 10:56 ET | 1776 | 8.075 |
| 10:58 ET | 17102 | 8.07 |
| 11:00 ET | 6872 | 8.06 |
| 11:02 ET | 4252 | 8.03 |
| 11:03 ET | 9040 | 8.0798 |
| 11:05 ET | 1320 | 8.078 |
| 11:07 ET | 2940 | 8.04 |
| 11:09 ET | 7398 | 8.0466 |
| 11:12 ET | 1600 | 7.95 |
| 11:14 ET | 9302 | 7.895 |
| 11:16 ET | 200 | 7.95 |
Nov 18, 2024
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer, from 7:00AM ET on Monday Nov 18, 2024 by Dow Jones
7:00AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 13, 2024
MindMed to Participate in Upcoming Investor Conferences, from 7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 11, 2024
DJ Mind Medicine Price Target Maintained With a $55.00/Share by HC Wainwright & Co., from 5:30AM ET on Monday Nov 11, 2024 by Dow Jones
5:30AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 7, 2024
Press Release: MindMed Reports Third Quarter 2024 Financial Results and Business Updates, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
4:01PM ET on Thursday Nov 07, 2024 by Dow JonesMindMed Reports Third Quarter 2024 Financial Results and Business Updates, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mind Medicine (MindMed) Inc | 554.4M | -4.0x | --- |
Humacyte Inc | 550.7M | -3.1x | --- |
Third Harmonic Bio Inc | 561.9M | -13.2x | --- |
Astria Therapeutics Inc | 544.5M | -4.7x | --- |
Annexon Inc | 543.1M | -5.1x | --- |
Corvus Pharmaceuticals Inc | 575.1M | -9.4x | --- |
Company Information
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Contact Information
- Headquarters
- One World Trade Center, Suite 8500NEW YORK, NY, United States 10007
- Phone
- 212-220-6633
- Fax
- 888-848-3972
Executives
- Independent Chairman of the Board
- Carol Vallone
- Executive President
- Miriam Wernli
- Chief Development Officer
- Robert Barrow
- Independent Vice Chairman of the Board
- Andreas Krebs
- Chief Accounting Officer
- Carrie Liao
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $554.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 73.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -6.69 |
EPS | $-1.99 |
Book Value | $1.90 |
P/E Ratio | -4.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
